{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:08:48Z","timestamp":1789006128362,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373160"],"award-info":[{"award-number":["82373160"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972632"],"award-info":[{"award-number":["81972632"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The MYC oncoprotein drives aggressive tumor behavior across many cancer types, yet its intrinsically disordered structure has limited direct pharmacologic targeting. Building on our previous kinome-wide CRISPR screen, we identify the receptor tyrosine kinase EphB4 as a druggable synthetic-lethal vulnerability in MYC-driven cancers. Genetic ablation or pharmacologic inhibition of EphB4 selectively triggers robust apoptosis in MYC-activated normal cells and MYC-high triple-negative breast cancer (TNBC) cell lines, while sparing MYC-low counterparts. This apoptotic response is Bcl-2-sensitive and p53-independent, overcoming a major resistance barrier in TNBC. In vivo, EphB4 inhibition markedly suppresses MYC-driven tumor growth. Notably, co-targeting EphB4 and Bcl-2 with ABT-199 yields synergistic apoptosis and induces tumor regression in TNBC models. Mechanistically, EphB4 inhibition leads to the selective transcriptional repression of PSMB5, the \u03b25 catalytic subunit of the proteasome, resulting in the impairment of proteasome activity and the induction of MYC-dependent apoptotic stress. This establishes an unexpected link between EphB4 signaling and proteostasis maintenance, a heightened dependency in MYC-overexpressing cells due to their elevated biosynthetic load. Targeting\n                    <jats:italic>PSMB5<\/jats:italic>\n                    transcription, rather than its catalytic active site, also provides a potential strategy to circumvent or delay resistance to conventional proteasome inhibitors. Together, these findings define the EphB4-PSMB5 axis as a mechanistically distinct and therapeutically actionable vulnerability in MYC-high TNBC, positioning EphB4 inhibition as a promising approach to treat MYC-driven cancers.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-09020-5","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T03:20:21Z","timestamp":1782444021000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["EphB4 inhibition defines a druggable synthetic-lethal vulnerability in MYC-driven triple-negative breast cancer"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6243-3575","authenticated-orcid":false,"given":"Zhe","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7384-2490","authenticated-orcid":false,"given":"Weidong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"9020_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","volume":"149","author":"CV Dang","year":"2012","unstructured":"Dang CV. MYC on the path to cancer. Cell. 2012;149:22\u201335.","journal-title":"Cell"},{"key":"9020_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","volume":"19","author":"R Dhanasekaran","year":"2022","unstructured":"Dhanasekaran R, Deutzmann A, Mahauad-Fernandez WD, Hansen AS, Gouw AM, Felsher DW. The MYC oncogene - the grand orchestrator of cancer growth and immune evasion. Nat Rev Clin Oncol. 2022;19:23\u201336.","journal-title":"Nat Rev Clin Oncol"},{"key":"9020_CR3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1126\/science.1071489","volume":"297","author":"M Jain","year":"2002","unstructured":"Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 2002;297:102\u20134.","journal-title":"Science"},{"key":"9020_CR4","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/nature03043","volume":"431","author":"CM Shachaf","year":"2004","unstructured":"Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature. 2004;431:1112\u20137.","journal-title":"Nature"},{"key":"9020_CR5","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nature05674","volume":"446","author":"OJ Sansom","year":"2007","unstructured":"Sansom OJ, Meniel VS, Muncan V, Phesse TJ, Wilkins JA, Reed KR, et al. Myc deletion rescues Apc deficiency in the small intestine. Nature. 2007;446:676\u20139.","journal-title":"Nature"},{"key":"9020_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1097-2765(00)80367-6","volume":"4","author":"DW Felsher","year":"1999","unstructured":"Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell. 1999;4:199\u2013207.","journal-title":"Mol Cell"},{"key":"9020_CR7","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nature07260","volume":"455","author":"L Soucek","year":"2008","unstructured":"Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, et al. Modelling Myc inhibition as a cancer therapy. Nature. 2008;455:679\u201383.","journal-title":"Nature"},{"key":"9020_CR8","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"9020_CR9","doi-asserted-by":"crossref","unstructured":"Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397:1750\u201369.","DOI":"10.1016\/S0140-6736(20)32381-3"},{"key":"9020_CR10","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9:176\u201398.","journal-title":"Cancer Discov"},{"key":"9020_CR11","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/nm.4213","volume":"22","author":"D Horiuchi","year":"2016","unstructured":"Horiuchi D, Camarda R, Zhou AY, Yau C, Momcilovic O, Balakrishnan S, et al. PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. Nat Med. 2016;22:1321\u20139.","journal-title":"Nat Med"},{"key":"9020_CR12","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1084\/jem.20111512","volume":"209","author":"D Horiuchi","year":"2012","unstructured":"Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med. 2012;209:679\u201396.","journal-title":"J Exp Med"},{"key":"9020_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1146\/annurev-pharmtox-010715-103440","volume":"56","author":"JS Lazo","year":"2016","unstructured":"Lazo JS, Sharlow ER. Drugging undruggable molecular cancer targets. Annu Rev Pharmacol Toxicol. 2016;56:23\u201340.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"9020_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-018-0008-7","volume":"3","author":"H Chen","year":"2018","unstructured":"Chen H, Liu H, Qing G. Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct Target Ther. 2018;3:5.","journal-title":"Signal Transduct Target Ther"},{"key":"9020_CR15","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.tips.2020.11.014","volume":"42","author":"DKH Thng","year":"2021","unstructured":"Thng DKH, Toh TB, Chow EK. Capitalizing on synthetic lethality of MYC to treat cancer in the digital age. Trends Pharm Sci. 2021;42:166\u201382.","journal-title":"Trends Pharm Sci"},{"key":"9020_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45128-y","volume":"15","author":"A Deutzmann","year":"2024","unstructured":"Deutzmann A, Sullivan DK, Dhanasekaran R, Li W, Chen X, Tong L, et al. Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma. Nat Commun. 2024;15:963.","journal-title":"Nat Commun"},{"key":"9020_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46572-6","volume":"15","author":"M Ye","year":"2024","unstructured":"Ye M, Fang Y, Chen L, Song Z, Bao Q, Wang F, et al. Therapeutic targeting nudix hydrolase 1 creates a MYC-driven metabolic vulnerability. Nat Commun. 2024;15:2377.","journal-title":"Nat Commun"},{"key":"9020_CR18","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1158\/0008-5472.CAN-22-2948","volume":"83","author":"P Lin","year":"2023","unstructured":"Lin P, Lourenco C, Cruickshank J, Palomero L, van Leeuwen JE, Tong AHY, et al. Topoisomerase 1 Inhibition in MYC-driven cancer promotes aberrant R-loop accumulation to induce synthetic lethality. Cancer Res. 2023;83:4015\u201329.","journal-title":"Cancer Res"},{"key":"9020_CR19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ccell.2014.11.024","volume":"27","author":"PA Carroll","year":"2015","unstructured":"Carroll PA, Diolaiti D, McFerrin L, Gu H, Djukovic D, Du J, et al. Deregulated Myc requires MondoA\/Mlx for metabolic reprogramming and tumorigenesis. Cancer Cell. 2015;27:271\u201385.","journal-title":"Cancer Cell"},{"key":"9020_CR20","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature14985","volume":"525","author":"TY Hsu","year":"2015","unstructured":"Hsu TY, Simon LM, Neill NJ, Marcotte R, Sayad A, Bland CS, et al. The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature. 2015;525:384\u20138.","journal-title":"Nature"},{"key":"9020_CR21","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/nature10927","volume":"483","author":"L Liu","year":"2012","unstructured":"Liu L, Ulbrich J, M\u00fcller J, Wustefeld T, Aeberhard L, Kress TR, et al. Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature. 2012;483:608\u201312.","journal-title":"Nature"},{"key":"9020_CR22","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1126\/science.1212728","volume":"335","author":"JD Kessler","year":"2012","unstructured":"Kessler JD, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, Schmitt EM, et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science. 2012;335:348\u201353.","journal-title":"Science"},{"key":"9020_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217803","volume":"625","author":"Z Sun","year":"2025","unstructured":"Sun Z, Wu R, Liang X, Shi T, Zhang Y, Pan Z, et al. MLCK inhibition induces synthetic lethality in MYC-driven cancer. Cancer Lett. 2025;625:217803.","journal-title":"Cancer Lett"},{"key":"9020_CR24","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1158\/0008-5472.CAN-21-1707","volume":"82","author":"Z Sun","year":"2022","unstructured":"Sun Z, Zhang Z, Wang QQ, Liu JL. Combined inactivation of CTPS1 and ATR is synthetically lethal to MYC-overexpressing cancer cells. Cancer Res. 2022;82:1013\u201324.","journal-title":"Cancer Res"},{"key":"9020_CR25","doi-asserted-by":"publisher","first-page":"244","DOI":"10.2174\/0113892037269589231017055642","volume":"25","author":"A Ullah","year":"2024","unstructured":"Ullah A, Razzaq A, Zhou C, Ullah N, Shehzadi S, Aziz T, et al. Biological significance of EphB4 expression in cancer. Curr Protein Pept Sci. 2024;25:244\u201355.","journal-title":"Curr Protein Pept Sci"},{"key":"9020_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.semcancer.2017.10.002","volume":"56","author":"Y Chen","year":"2019","unstructured":"Chen Y, Zhang H, Zhang Y. Targeting receptor tyrosine kinase EphB4 in cancer therapy. Semin Cancer Biol. 2019;56:37\u201346.","journal-title":"Semin Cancer Biol"},{"key":"9020_CR27","unstructured":"ClinicalTrials.gov. A Phase IIa Trial of sEphB4-HSA in Combination With Anti PD-1 Antibody (Pembrolizumab, MK3475) in Patients With Non-small Cell Lung and Head\/Neck Cancer. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03049618 2025."},{"key":"9020_CR28","unstructured":"ClinicalTrials.gov. A Phase II Study of sEphB4-HSA in Kaposi Sarcoma. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02799485?term=EphB4&page=1&rank=1 2025."},{"key":"9020_CR29","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10456-010-9183-z","volume":"13","author":"G Martiny-Baron","year":"2010","unstructured":"Martiny-Baron G, Holzer P, Billy E, Schnell C, Brueggen J, Ferretti M, et al. The small molecule-specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF- driven angiogenesis. Angiogenesis. 2010;13:259\u201367.","journal-title":"Angiogenesis"},{"key":"9020_CR30","doi-asserted-by":"publisher","first-page":"6242","DOI":"10.1016\/j.bmcl.2010.08.100","volume":"20","author":"C Bardelle","year":"2010","unstructured":"Bardelle C, Barlaam B, Brooks N, Coleman T, Cross D, Ducray R, et al. Inhibitors of the tyrosine kinase EphB4. Part 3: identification of non-benzodioxole-based kinase inhibitors. Bioorg Med Chem Lett. 2010;20:6242\u20135.","journal-title":"Bioorg Med Chem Lett"},{"key":"9020_CR31","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","volume":"112","author":"R Oerlemans","year":"2008","unstructured":"Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 2008;112:2489\u201399.","journal-title":"Blood"},{"key":"9020_CR32","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.exphem.2009.04.001","volume":"37","author":"S Lu","year":"2009","unstructured":"Lu S, Yang J, Chen Z, Gong S, Zhou H, Xu X, et al. Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma\/leukemia cells derived from the Jurkat cell line. Exp Hematol. 2009;37:831\u20137.","journal-title":"Exp Hematol"},{"key":"9020_CR33","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/leu.2010.137","volume":"24","author":"M Ri","year":"2010","unstructured":"Ri M, Iida S, Nakashima T, Miyazaki H, Mori F, Ito A, et al. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia. 2010;24:1506\u201312.","journal-title":"Leukemia"},{"key":"9020_CR34","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/nrm1662","volume":"6","author":"EB Pasquale","year":"2005","unstructured":"Pasquale EB. Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol. 2005;6:462\u201375.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"9020_CR35","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/nrd2662","volume":"7","author":"S Storey","year":"2008","unstructured":"Storey S. Targeting apoptosis: selected anticancer strategies. Nat Rev Drug Discov. 2008;7:971\u20132.","journal-title":"Nat Rev Drug Discov"},{"key":"9020_CR36","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/ng.3468","volume":"48","author":"P Ulz","year":"2016","unstructured":"Ulz P, Heitzer E, Speicher MR. Co-occurrence of MYC amplification and TP53 mutations in human cancer. Nat Genet. 2016;48:104\u20136.","journal-title":"Nat Genet"},{"key":"9020_CR37","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/22780","volume":"400","author":"WC Hahn","year":"1999","unstructured":"Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature. 1999;400:464\u20138.","journal-title":"Nature"},{"key":"9020_CR38","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1128\/MCB.22.7.2111-2123.2002","volume":"22","author":"WC Hahn","year":"2002","unstructured":"Hahn WC, Dessain SK, Brooks MW, King JE, Elenbaas B, Sabatini DM, et al. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol. 2002;22:2111\u201323.","journal-title":"Mol Cell Biol"},{"key":"9020_CR39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1101\/gad.828901","volume":"15","author":"B Elenbaas","year":"2001","unstructured":"Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 2001;15:50\u201365.","journal-title":"Genes Dev"},{"key":"9020_CR40","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ccell.2019.10.001","volume":"36","author":"H Han","year":"2019","unstructured":"Han H, Jain AD, Truica MI, Izquierdo-Ferrer J, Anker JF, Lysy B, et al. Small-molecule MYC inhibitors suppress tumor growth and enhance immunotherapy. Cancer Cell. 2019;36:483\u201397.e415.","journal-title":"Cancer Cell"},{"key":"9020_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56782-1","volume":"16","author":"DE Ramage","year":"2025","unstructured":"Ramage DE, Grant DW, Timms RT. Loss-of-function mutations in the dystonia gene THAP1 impair proteasome function by inhibiting PSMB5 expression. Nat Commun. 2025;16:1511.","journal-title":"Nat Commun"},{"key":"9020_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56867-x","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang Y, Wang Y, Iriki T, Hashimoto E, Inami M, Hashimoto S, et al. The DYT6 dystonia causative protein THAP1 is responsible for proteasome activity via PSMB5 transcriptional regulation. Nat Commun. 2025;16:1600.","journal-title":"Nat Commun"},{"key":"9020_CR43","doi-asserted-by":"crossref","unstructured":"Oki S, Ohta T, Shioi G, Hatanaka H, Ogasawara O, Okuda Y, et al. ChIP-Atlas: a data-mining suite powered by full integration of public ChIP-seq data. EMBO Rep 2018;19:e46255.","DOI":"10.15252\/embr.201846255"},{"key":"9020_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-28107-4","volume":"8","author":"A Castell","year":"2018","unstructured":"Castell A, Yan Q, Fawkner K, Hydbring P, Zhang F, Verschut V, et al. A selective high-affinity MYC-binding compound inhibits MYC:MAX interaction and MYC-dependent tumor cell proliferation. Sci Rep. 2018;8:10064.","journal-title":"Sci Rep"},{"key":"9020_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00303-6","volume":"6","author":"ZI Mitri","year":"2022","unstructured":"Mitri ZI, Abuhadra N, Goodyear SM, Hobbs EA, Kaempf A, Thompson AM, et al. Impact of TP53 mutations in triple negative breast cancer. NPJ Precis Oncol. 2022;6:64.","journal-title":"NPJ Precis Oncol"},{"key":"9020_CR46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2308807120","volume":"120","author":"D Dibra","year":"2023","unstructured":"Dibra D, Moyer SM, El-Naggar AK, Qi Y, Su X, Lozano G. Triple-negative breast tumors are dependent on mutant p53 for growth and survival. Proc Natl Acad Sci USA. 2023;120:e2308807120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"9020_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.759154","volume":"9","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Hao R, Guo Q, Zhang S, Wang X. TP53 mutation infers a poor prognosis and is correlated to immunocytes infiltration in breast cancer. Front Cell Dev Biol. 2021;9:759154.","journal-title":"Front Cell Dev Biol"},{"key":"9020_CR48","doi-asserted-by":"crossref","unstructured":"Valente LJ, Tarangelo A, Li AM, Naciri M, Raj N, Boutelle AM, et al. p53 deficiency triggers dysregulation of diverse cellular processes in physiological oxygen. J Cell Biol. 2020;219:e201908212.","DOI":"10.1083\/jcb.201908212"},{"key":"9020_CR49","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ccell.2019.01.006","volume":"35","author":"A Carugo","year":"2019","unstructured":"Carugo A, Minelli R, Sapio L, Soeung M, Carbone F, Robinson FS, et al. p53 is a master regulator of proteostasis in smarcb1-deficient malignant rhabdoid tumors. Cancer Cell. 2019;35:204\u201320.e209.","journal-title":"Cancer Cell"},{"key":"9020_CR50","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41418-018-0246-9","volume":"26","author":"F Mantovani","year":"2019","unstructured":"Mantovani F, Collavin L, Del Sal G. Mutant p53 as a guardian of the cancer cell. Cell Death Differ. 2019;26:199\u2013212.","journal-title":"Cell Death Differ"},{"key":"9020_CR51","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40268-019-0269-9","volume":"19","author":"P Robak","year":"2019","unstructured":"Robak P, Robak T. Bortezomib for the treatment of hematologic malignancies: 15 Years Later. Drugs R D. 2019;19:73\u201392.","journal-title":"Drugs R D"},{"key":"9020_CR52","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1124\/pr.117.015370","volume":"71","author":"TA Thibaudeau","year":"2019","unstructured":"Thibaudeau TA, Smith DM. A practical review of proteasome pharmacology. Pharm Rev. 2019;71:170\u201397.","journal-title":"Pharm Rev"},{"key":"9020_CR53","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/s41375-020-0989-4","volume":"35","author":"K Allmeroth","year":"2021","unstructured":"Allmeroth K, Horn M, Kroef V, Miethe S, Muller RU, Denzel MS. Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma. Leukemia. 2021;35:887\u201392.","journal-title":"Leukemia"},{"key":"9020_CR54","doi-asserted-by":"publisher","first-page":"10317","DOI":"10.1021\/jm300434z","volume":"55","author":"AJ Kale","year":"2012","unstructured":"Kale AJ, Moore BS. Molecular mechanisms of acquired proteasome inhibitor resistance. J Med Chem. 2012;55:10317\u201327.","journal-title":"J Med Chem"},{"key":"9020_CR55","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jgg.2018.11.006","volume":"46","author":"Z Sun","year":"2019","unstructured":"Sun Z, Liu JL. mTOR-S6K1 pathway mediates cytoophidium assembly. J Genet Genomics. 2019;46:65\u201374.","journal-title":"J Genet Genomics"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09020-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09020-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09020-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:45:33Z","timestamp":1789004733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09020-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9020"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-09020-5","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. All animal experiments were approved by the Institutional Animal Care and Use Committee of Shanghai University of Traditional Chinese Medicine (Approval Number: PZSHUTCM2504250018). This study did not involve human participants, human tissue samples, or identifiable human images; therefore, informed consent to participate and consent for publication were not applicable.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"792"}}